Strike Pharma are developing a novel next generation Antibody-Drug Conjugate (ADC) technology within the immuno-oncology precision medicine space, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve the delivery of tailor-made synthetic molecules to specific cell types for improved immune modulation.
Location: Sweden, Uppsala
Investors 2
| Date | Name | Website |
| 03.03.2022 | Flerie Inv... | flerie.com |
| - | Eir Ventur... | eirventure... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 09.02.2023 | Health tech startups are developing a personalised approach ... | Diagnosing and treating complex health conditions has plagued health professionals forever. In respo... | tech.eu/20... |